Skip to main content

Table 1 Phosphodiesterase inhibitors assessed in clinical trials (2016–2020) [5, 25,26,27,28] (Year refers to the years in which the agent is listed on clinicaltrials.gov as being in a clinical trial)

From: New approaches to symptomatic treatments for Alzheimer’s disease

Year Agent PDE Target Phase Outcome
2020, 2019 BPN14770 4 2 Synaptic, neuroprotection, anti-inflammatory
2020, 2019, 2018, 2017, 2016 Cilostazol 3 2 Synaptic plasticity and neuroprotection; improved circulation
2019 AR1001 5 2 Synaptic plasticity and amyloid reduction
2017, 2016 BI 409306 9A 3 Cognitive enhancer
\